My Market Wizard

Filing Category: Completion of Acquisition or Disposition of Assets

  • TransMedics Group, Inc. 8-K Analysis & Summary – 2/21/2025

    Analyst Summary

    • TransMedics Group, Inc. acquired a fixed-wing aircraft from Ocean Select Seafood, L.L.C. for approximately $14.3 million.
    • The company intends to use the acquired aircraft to transport donor organs as part of its National OCS Program.
    • The acquisition is considered a series of related transactions with respect to acquiring a fleet of aircraft.

    Potential Implications

    Company Performance

    • The acquisition of the aircraft is expected to enhance the company’s ability to transport donor organs efficiently.
    • The expansion of the aircraft fleet may lead to increased service capacity and revenue generation for the National OCS Program.

  • Cyclacel Pharmaceuticals, Inc. 8-K Analysis & Summary – 3/14/2025

    Analyst Summary

    • Cyclacel Pharmaceuticals, Inc. acquired assets related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor, from its wholly-owned subsidiary, Cyclacel Limited (in liquidation), for £250,000.
    • The assets include rights related to the treatment of esophageal cancer and acute leukemia.
    • The Purchase Agreement stipulates that if Cyclacel Pharmaceuticals disposes of the assets in the future, Cyclacel Limited is entitled to 50% of the surplus, defined as the difference between the disposal consideration and the greater of £250,000 or £250,000 plus direct costs incurred by Cyclacel in the research or development of the assets.
    • An Assignment of Patent Rights Agreement was also entered into, transferring all rights, title, and interest in certain patent rights related to Plogo from Cyclacel Limited to Cyclacel Pharmaceuticals.
    • The company is obligated to only make any Subsequent Disposal for a cash consideration.
    • The Buyer shall obtain fair value customary in an arms-length transaction of the type proposed by it for any Subsequent Disposal.